OTLK · Outlook Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.41M | - | - | - | - | - |
| Cost of Revenue | $1.36M | - | - | - | - | - |
| Gross Profit | $57.2K | - | - | - | - | - |
| R&D | $27.18M | $41.76M | $26.45M | $42.33M | $38.96M | $26.34M |
| SG&A | $29.94M | $29.94M | $26.67M | $20.74M | $12.77M | $9.97M |
| Total Operating Expenses | - | - | - | - | $51.73M | $36.84M |
| D&A | $117.1K | $113.9K | $44.2K | $204.7K | $262.1K | $219.4K |
| Operating Income | ($67.06M) | ($71.70M) | ($53.13M) | ($63.07M) | ($51.73M) | ($36.84M) |
| Interest Expense | - | $3.16M | - | - | - | $1.76M |
| Income Tax | ($1.55M) | $2.8K | $2.8K | $2.8K | $2.0K | ($3.27M) |
| Net Income | ($62.42M) | ($75.37M) | ($58.98M) | ($66.05M) | ($53.16M) | ($35.24M) |
| EPS - Basic | ($1.79) | ($4.06) | ($4.80) | ($6.20) | ($13.40) | - |
| EPS - Diluted | ($1.79) | ($4.06) | ($4.80) | ($6.20) | ($13.40) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.08M | $14.93M | $23.39M | $17.40M | $14.48M | $12.54M |
| Accounts Receivable | $1.49M | - | - | - | - | - |
| Inventory | $3.34M | - | - | - | - | - |
| Accounts Payable | $10.19M | $7.97M | $6.57M | $3.49M | $2.20M | $2.39M |
| Current Assets | $17.39M | $27.42M | $30.98M | $27.52M | $21.51M | $17.94M |
| Total Assets | $18.58M | $28.82M | $32.30M | $28.53M | $22.81M | $19.73M |
| Current Liabilities | $45.81M | $42.55M | $46.73M | $19.73M | $6.75M | $15.89M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $50.77M | $101.90M | $46.74M | $19.79M | $18.20M | $16.91M |
| Stockholders' Equity | ($32.19M) | ($73.08M) | ($14.44M) | $8.74M | $4.61M | $2.83M |
| Retained Earnings | ($605.71M) | ($543.28M) | ($467.92M) | ($408.94M) | ($342.88M) | ($289.72M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($51.83M) | ($68.79M) | ($42.97M) | ($56.67M) | ($54.25M) | ($31.79M) |
| Investing Cash Flow | - | - | - | - | - | ($900.0K) |
| Financing Cash Flow | $44.98M | $60.33M | $48.97M | $59.59M | $56.19M | $37.21M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 4.0% | - | - | - | - | - |
| Operating margin | -4744.3% | - | - | - | - | - |
| EBITDA margin | -4736.0% | - | - | - | - | - |
| Net margin | -4416.2% | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | 1922.9% | - | - | - | - | - |
| SG&A / Revenue | 2118.1% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -335.9% | -261.5% | -182.6% | -231.5% | -233.1% | -178.6% |
| Return on equity | 193.9% | 103.1% | 408.5% | -756.0% | -1153.9% | -1246.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 |
| Quick ratio | 0.31 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 |
| Cash ratio | 0.18 | 0.35 | 0.50 | 0.88 | 2.14 | 0.79 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -22.7x | - | - | - | -21.0x |
| Equity multiplier | -0.58 | -0.39 | -2.24 | 3.27 | 4.95 | 6.98 |
| Liabilities / Assets | 2.73 | 3.54 | 1.45 | 0.69 | 0.80 | 0.86 |
| Efficiency | ||||||
| Asset turnover | 0.08 | - | - | - | - | - |
| Inventory turnover | 0.41 | - | - | - | - | - |
| Days sales outstanding | 385d | - | - | - | - | - |
| Days inventory outstanding | 898d | - | - | - | - | - |
| Days payable outstanding | 2743d | - | - | - | - | - |
| Cash conversion cycle | -1459d | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | 592.3x | 683.4x | - |
| P / S | 26.1x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 6.5% | -35.0% | 15.8% | -21.9% | -40.4% | -1.5% |
| Net income growth (YoY) | 17.2% | -27.8% | 10.7% | -24.2% | -50.9% | -2.1% |
| EPS growth (YoY) | 55.9% | 15.4% | 22.6% | 53.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 56.0% | -406.1% | - | 89.6% | 63.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$1.41M totalDevelopment And Commercialization Of Ons5010 Or Lytenava$1.41M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-40.10
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Outlook Therapeutics against the 5 most active filers in the same SIC group.